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Anthranilic acid (ANA) and 3-hydroxyanthranilic acid (3-HANA) are kynurenine pathway intermediates
of the tryptophan metabolism. A hitherto unemployed method combination, differential pulse voltam-
metry, mass spectrometry (nano-ESIeMS), deoxyribose degradation and iron(II) autoxidation assays has
been employed for studying of their redox chemistry and their interactions with iron(II) and iron(III)
ions. Both acids inhibited the Fenton reaction by iron chelation and ROS scavenging in the deoxyribose
degradation assay. In the iron(II) autoxidation assay, anthranilic acid showed antioxidant effects, whereas
3-hydroxyanthranilic acid exhibited apparent pro-oxidant activity. The differential pulse voltammograms
of free metabolites and their iron(II) coordination complexes reﬂected these properties. Nano-ESIeMS
conﬁrmed ANA and 3-HANA as efﬁcient iron(II) chelators, both of which form coordination complexes of
ligand:iron(II) ratio 1:1, 2:1, and 3:1. In addition, nano-ESIeMS analyses of the oxidation effects by hy-
droxyl radical attack identiﬁed 3-HANA as strikingly more susceptible than ANA. 3-HANA susceptibility
to oxidation may explain its decreased concentrations in the reaction mixture. The presented observa-
tions can add to explaining why 3-HANA levels decrease in patients with some neurological and other
diseases which can often associated with elevated concentrations of ROS.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Anthranilic acid (2-aminobenzoic acid, ANA) and 3-
hydroxyanthranilic acid (3-HANA) (Fig. 1) are metabolic in-
termediates of the kynurenine pathway starting from tryptophan.
This pathway is responsible primarily for the biosynthesis of
nicotinamide that is required for biosynthesis of NAD(P)H, a
fundamental cellular electron donator [1]. In plants, ANA and 3-
HANA are used for quinoline and acridine alkaloid synthesis [2].
In pharmaceutical industry, ANA served as a basic model compound
for synthesis of fenamates (a group of anti-inﬂammatory drugs).
During the last decades, ANA and 3-HANA have been recognized
to affect brain and immune system function. Patients withx: þ43 1 4277 9542.
hobot).
r B.V. This is an open access articlneurological disorders usually show marked changes in the levels
of these two tryptophan metabolites [3e5]. 3-HANA concentration
as well as the 3-HANA:ANA ratio decrease in patients suffering from
stroke, chronic brain injury and Huntington's disease, among
others [6,7]. ANA and 3-HANA can inﬂuence ROS concentrations by
formation of coordination complexes with iron [3]. In the human
brain, ROS may arise as a product of iron(II) autoxidation and the
Fenton chemistry [8,9]. Whereas ANA is nearly exclusively known
for antioxidant activity [3,10], 3-HANA's documented activities
include both antioxidant [3,10e12] and pro-oxidant effects
[3,13e15]. So far, the mechanism behind the reversed 3-HANA:ANA
ratio in patients is not understood well.
Although the redox and chelation properties of both acids have
been investigated extensively in the last decades, some studies
demonstrated controversial results. This stimulated us to explore
these two speciﬁc tryptophan metabolites in more detail by
employing a set of methods that have not yet been used in thise under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Structures of a) anthranilic acid (ANA) and b) 3-hydroxyanthranilic acid (3-
HANA).
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and direct infusion mass spectrometry (nano-ESIeMS), deoxyri-
bose degradation and iron(II) autoxidation assays.
Material and methods
Chemicals
All chemicals used were purchased from SigmaeAldrich
(Schnelldorf, Germany). Water had Milli-Q quality.
Differential pulse voltammetry
Voltammetric curves were recorded in a three-electrode system,
mAutolab PGSTAT type III (EcoChemie Inc., Utrecht, The
Netherlands). The working electrode was a glassy carbon electrode
of 3 mm diameter, an Ag/AgCl (saturated KCl) electrode was used as
reference, and platinum wire as a counter electrode. The glassy
carbon electrode was washed with water and then polished by
aluminium oxide powder (0.3 mm of grain size) before every
measurement. The effective scan rate of the voltammetry was
21 mV s1, step potential was 5.25 mV, modulation amplitude was
25 mV, modulation time was 50 ms, and interval time was 250 ms.
Scan potential was from500 toþ1200mV. FeSO4 was dissolved in
degassed water at a concentration 10 mM. The stock solutions of
the measured acids were prepared by dissolving in degassed buffer
(0.1 M phosphate buffer pH 7.4). The ionic strength of the buffer
was 1 M and it was adjusted by K2SO4. The samples for the elec-
trochemical measurements of the acids were prepared bymixing of
1 mL their stock solution with 8 mL of the buffer and 1 mL of water.
The ﬁnal concentration of the acid was 1 mM. The samples for the
coordination complex analysis were prepared by mixing 1 mL of
aqueous FeSO4 solution with 9 mL of the degassed buffer or buf-
fereanthranilic or 3-HANA solution. The ﬁnal applied concentra-
tion ratio of acid:Fe was 4:1. The solutions of electrolytes were
degassed by argon for 10 min and measurements were carried out
under argon atmosphere at a room temperature.
Mass spectrometry analyses
MS analyses were performed out on a Thermo Electron
LTQ-Orbitrap XL mass spectrometer equipped with a nano elec-
trospray ion source (ThermoFisher Scientiﬁc, Bremen, Germany)
and operated under Xcalibur software, in the positive ionization
mode. The instrument was calibrated using the manufacturer's
calibration standards. The Fourier transformed full scan mass
spectra were acquired at a target value of 106 ions with a resolution
of 100,000 in the m/z range of 80e2000. In order to achieve even
higher mass accuracy, a lock mass option was enabled and the
cyclomethicone N5 ions generated in the electrospray process from
ambient air (m/z ¼ 371.101230) were used for internal recalibration
in real time. This allowed mass accuracies of <1 ppm. Speciﬁc tunesettings for the MS were as follows: spray voltage was set to 1.8 kV;
capillary voltage was 45 V, tube lens offset 150 V and capillary
temperaturewas set at 180 C, no sheath gas and auxiliary gas were
used. ANA and 3-HANA coordination complexes were measured
according to a modiﬁed method that was published previously by
Sarowar et al. [16]. The samples for the nano-ESIeMS analysis of
ANA and 3-HANAe FeII complexes were prepared from a 1 mM
stock solution of ANA or 3-HANA in degassed methanol by adding
of appropriate amount of degassed aqueous FeCl2 solution
(500 mM) in the (ANA or 3-HANA: Fe) molar ratios 1:1, 2:1, 3:1, and
4:1. Before the measurement, the samples were diluted 1:10 or
1:100 with water/methanol (50:50, v:v) mixture. For the nano-
ESIeMS measurement, gold coated glass emitters (DNU-MS GbR,
Berlin, Germany) with 5 mL of this ﬁnal sample were used. The
samples for nano-ESIeMS analyses of anthranilic and 3-
hydroxyanthranilic acid oxidation stability were prepared as fol-
lowed: The tested compound was dissolved in aqueous ammonium
bicarbonate buffer solution (10 mM, pH 7.4 adjusted with HCl) to
1 mM solution. To 500 mL of this solution, 300 mL of 10 mM aqueous
ammonium bicarbonate buffer, 100 mL of degassed aqueous FeCl2
solution (100 mM) and 100 mL of aqueous H2O2 solution (55 mM)
were added. Standard 1.5 mL sample vials (La-Pha-Pack, Werner
Reifferscheidt GmbH, Langerwehe, Germany) were used as reaction
vials. The reaction mixtures was incubated at 27 C and analyzed in
reaction times 3 and 8 h. For the nano-ESIeMSmeasurement, 50 mL
of the reaction mixturewas diluted with 450 mL of 0.2% (v/v) formic
acid in methanol and glass emitters (DNU-MS GbR, Berlin, Ger-
many) ﬁlled with 5 mL of this mixture were used. The isotope exact
masses of the complex ions and all other designated ions were
calculated with ChemDoodle 7.0.2, iChemLabs, LLC, Somset, NY.
Deoxyribose degradation assay
The deoxyribose degradation assay and its various variants
follow published procedures [17]. ANA or 3-HANAwas dissolved in
aqueous KH2PO4/KOH buffer solution (30 mM, pH 7.4) and diluted
serially; to 125 mL of this solution, 25 mL of a 10.4 mM 2-deoxy-D-
ribose solution in the same buffer system and 50 mL of FeCl3 (FeCl3
variant) or FeIIIEDTA (FeIIIEDTA variant) solution (50 mM) were
added. The complex of FeIII with EDTAwas prepared separately; the
104 mMEDTA solution in the buffer was premixed with the aqueous
100 mM FeCl3 solution (1:1, v/v). Further, 25 mL of 10.0 mM aqueous
solution H2O2 and 25 mL of 1.0 mM ascorbic acid in the buffer were
added to start the Fenton reaction in the H2O2/FeIII/ascorbic acid
reaction mixture. In the other deoxyribose degradation assay sys-
tems, H2O2 or ascorbic acid was replaced by the same volume of
water or buffer, respectively. The ﬁnal concentrations of the tested
acids were 2e500 mM. Thiobarbituric acid reactive species (TBARS)
were determined photometrically at 532 nm after reaction with
thiobarbituric acid and subsequent extraction of the pink pigment
with 1-butanol. The H2O2/FeIII/ascorbic acid reaction mixture
served as positive control and represented 100% TBARS detection in
all variants and also served as comparative standard for each
experiment. Blanks contained the full reaction mixtures except for
2-deoxy-D-ribose and were determined in each experiment. Ex-
periments were performed in triplicates. The temperature during
incubation was 27 C. Variants containing H2O2 were evaluated
after 1 h; variants without H2O2 were evaluated after 16 h
incubation.
FeII autoxidation assay
The assay was carried out according procedures published
elsewhere [18,19]. The sample was dissolved in aqueous KH2PO4/
KOH buffer solution (30 mM, pH 7.4) and diluted serially; to 125 mL
Fig. 2. Differential pulse voltammetry of a) anthranilic acid (ANA) and 3-
hydroxyanthranilic acid (3-HANA), b) anthranilic acidiron(II) solution 4:1 and c) 3-
hydroxyanthranilic acidiron(II) solution 4:1.
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same buffer system, 50 mL of the buffer, and 50 mL of degassed
aqueous FeSO4 solution (50 mM) were added. The ﬁnal concentra-
tions of the tested compounds were 2e500 mM. Blanks contained
the full reaction mixtures except for 2-deoxy-D-ribose. Standard
1.5 mL sample vials (La-Pha-Pack, Werner Reifferscheidt GmbH,
Langerwehe, Germany) were used as reaction vials. The mixtures
were incubated at 27 C for 16 h. Thereafter, 250 mL of 1.0% thio-
barbituric acid dissolved in 3% trichloroacetic acid (w/v) was added
to each vial to detect TBARS. The vials were heated in a water bath
at 80 C for 30 min. The reaction was stopped by transferring the
vials into an ice water bath for 3 min. To extract the TBARS, 600 mL
of 1-butanol was added, and the mixture was rigorously vortexed.
The butanol layers of the vials, each 350 mL, were pipetted into ﬂat
bottomed 96 well plates (Greiner, Kremsmünster, Austria), and the
absorbance was determined with a microplate reader (Tecan
Inﬁnite M200, M€annedorf, Switzerland) at 532 nm. Experiments
were performed in triplicate. Reaction mixtures lacking the test
compound served as the positive control (100% TBARS). The
phosphate buffer and water, which were used as solvents for the
tested substances or FeSO4, were degassed by argon for 10 min at
least.
Statistical analysis
Statgraphics Centurion XVI (Statistical Graphics Corp., Rockville,
MD, USA) was used to perform analyses of variance (ANOVA)
employing 95% Duncan's multiple range post hoc test.
Results and discussion
The differential pulse voltammogram (DPV) of ANA showed one
peak at 766 mV (peak 1), corresponding to oxidation of the amino
group (Fig. 2a), and 3-HANA two peaks, at 242 and 947 mV corre-
sponding to the hydroxyl group and amino group oxidations,
respectively (Fig. 2a). The voltammetry proved that both tested
acids are redox active compounds. The more negative redox po-
tential of the 3-HANA phenolic hydroxyl group suggests that it is
the more potent reducing agent of the two compounds. Ortho-
aminophenols, such as 3-HANA, usually exhibit redox activity
because of their easy oxidation to quinone imines [15,20].
In addition, ANA and 3-HANA were investigated for their
possible capability of forming coordination complexes with iron(II).
The voltammogram demonstrated that iron(II) ions formed various
coordination complexes with phosphate (buffer component),
which resulted in a broad dominant peak with two maxima at the
potentials at 235 mV (peak maximum 1) and 18 mV (peak
maximum 2) (Fig. 2b). When iron(II) solutionwas added to the ANA
solution, a new broad peak at 278 mV (peak 3, Fig. 2b) appeared in
the voltammogram; the peak current of the amino group oxidation
evidently decreased and the peak oxidation potential increased to
833 mV (peak 4). In the case of 3-HANA, no peaks of Fe3-HANA
complexes were visible (Fig. 2c). However, the oxidation peak of
the hydroxyl group was shifted into the anodic direction (peak 1).
The peak potential of the amino group oxidation remained un-
changed (peak 2). A possible explanation for this phenomenon
could be that many different iron coordination complexes with
3-HANA as ligand are formed, all of which were present in too low
concentrations to allow unambiguous discrimination from the
baseline.
Consequently, coordination complex formation of ANA and
3-HANA with iron(II) was explored by nano-ESIeMS (Fig. 3). This
method is applicable for characterizing metal complexes because it
provides direct information about possible stoichiometry of metal
coordination complexes [16,21,22]. The ESIeMS spectra proved thecapability of ANA and 3-HANA to form coordination complexes
with iron(II). The nano-ESIeMS measurements were carried out
with solutions of ANA or 3-HANA with iron(II) ions. The mass
spectrum of iron(II)ANA solution (Fig. 3a) showed the expected
peaks of ANA ([M þ H]þ,m/z 138.0551 (calc.m/z 138.0549) andm/z
160.0370 [M þ Na]þ (calc. m/z 160.0370).
a)
b)
Fig. 3. ESIeMS spectra in the positive mode of a) anthranilic acid (ANA)iron(II) solution 4:1 and b) 3-hydroxyanthranilic acid (3-HANA)iron(II) solution 2:1.
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224.0005) corresponds to a coordination complex ion with one
ANA ligand [MH þ FeII þ CH3OH]þ. The following iron isotopes
were detectable: C8H1054FeNO3, m/z 222.0053, calc. m/z 222.0052,
rel. int. 6%, calc. rel. int., 6%; C8H1056FeNO3, rel. int. 100%, calc. rel.
int. 100%; C8H1057FeNO3, m/z 225.0039, calc. m/z 225.0038, rel. int.
7%, calc. rel. int. 9%; C8H1058FeNO3, m/z 226.0044, calc. m/z
226.0043, rel. int. 0.2%, calc. relative int. 0.2%.
A further metal complex ions was detected atm/z 329.0219 that
corresponds to [2MHþ FeII]þ, C14H1356FeN2O4, calc.m/z 329.0219.The following iron isotope ions were detectable: C14H1354FeN2O4,
327.0267, calc. 327.0266, rel. int. 6%, calc. rel. int. 6%;
C14H1356FeN2O4, rel. int. 100%, calc. rel. int. 100%; C14H1357FeN2O4,
m/z 330.0254, calc. rel. int. 330.0252, rel. int. 14%, calc. rel. int. 15%;
C14H1358FeN2O4,m/z 331.0263, calc.m/z 331.0262, rel. int. 0.3%, calc.
rel. int. 0.3%.
An m/z 351.0039 (C14H1256FeN2NaO4, calc. m/z 351.0038) rep-
resented the Na adduct of the former complex
[2Me2H þ FeII þ Na]þ. The following iron isotope ions were
detectable: C14H1254FeN2NaO4, m/z 349.0087, calc. m/z 349.0085,
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100%; C14H1257FeN2NaO4, m/z 352.0071, calc. m/z 352.0073, rel. int.
14%, calc. rel. int. 15%, C14H1258FeN2NaO4, m/z 353.0055, calc. m/z
353.0057, rel. int. 0.3%, calc. rel. int. 0.3%.
A further ion detected at m/z 466.0694 was assigned to
C21H2056FeN3O6, [3MH þ FeII]þ, calc. m/z 466.0693. The following
iron isotope ions were detectable: C21H2054FeN3O6, m/z 464.0742,
calc.m/z 464.0739, rel. int. 4%, calc. rel. int. 6%; C21H2056FeN3O6, rel.
int. 100%, calc. rel. int. 100%; C21H2057FeN3O6, m/z 467.0726, calc.
m/z 467.0727, rel. .int. 20%, calc. rel. int. 22%; C21H2058FeN3O6, m/z
468.0734, calc. m/z 468.0732, calc. rel. int. 0.5%.
In the ESIeMS spectrum of iron(II)3-HANA solution, a promi-
nent peak at m/z 154.0499 was identiﬁed as the protonated ion of
3-HANA [M þ H]þ, calc. 154.0500. (Fig. 3b). The 3-HANA adduct
with sodium ([M þ Na]þ) appeared as m/z 176.0319 signal (calc.
176.0318).
The ﬁrst metal complex was assigned to the ion
[MH þ FeII þ CH3OH]þ, C8H1056FeNO4, m/z 239.9955, calc. m/z
239.9955. The following iron isotope ions were detectable:
C8H1054FeNO4, m/z 238.0002, calc. m/z 238.0000, rel. int. 6%, calc.
rel. int. 6%; C8H1056FeNO4, rel. int. 100%, calc. rel. int. 100%;
C8H1057FeNO4,m/z 240.9988, calc.m/z 240.9987, rel. int. 8%, calc. rel.
int. 8%); C8H1058FeNO4, m/z 241.9994, calc. m/z 241.9996, rel. int.
0.5%, calc. rel. int. 0.8%.
A further metal complex ion with two 3-HANA ligands had an
m/z 361.0117 that correspond to [2MH þ FeII]þ, C14H1356FeN2O6,
calc.m/z 361.0117. The following iron isotope ions were detectable:
C14H1354FeN2O6, m/z 359.0165, calc. m/z 359.0164, rel. int. 6%, calc.
rel. int. 6%; C14H1356FeN2O6, rel. int. 100%, calc. rel. int. 100%;Fig. 4. Effects of anthranilic acid and 3-hydroxyanthranilic acid on generation of thiobarb
enediaminetetraacetic acid. Error bars indicate the standard deviation of three replicates; lC14H1357FeN2O6, m/z 362.0151, calc. m/z 362.0150, rel. int. 15%, calc.
rel. int. 15%; C14H1358FeN2O6, m/z 363.0189, calc. m/z 363.0185, rel.
int. 0.7%, calc. rel. int. 1%.
A metal complex ion with three 3-HANA ligands was identiﬁed
atm/z 514.0541, corresponding to C21H2056FeN3O9, [3MH þ FeII]þ,
calc.m/z 514.0541. The following iron isotope ions were detectable:
C21H2054FeN3O9, m/z 512.0588, calc. m/z 512.0588, rel. int. 3%, calc.
int. 6%; C21H2056FeN3O9, rel. int. 100%, calc. rel. int. 100%;
C21H2057FeN3O9, m/z 515.0576, calc. m/z 515.0574, rel. int. 18%, calc.
rel. int. 22%; C21H2058FeN3O9, m/z 516.0578, calc. m/z 516.0583, rel.
int. 2%, calc. rel. int. 2%.
All ions mentioned above were detected with different in-
tensities in ANA or 3-HANA: Fe molar ratios 1:1, 2:1, 3:1 and 4:1
(data not shown). These observations were corroborated by the
deoxyribose degradation assay results (Fig. 4). The principal
chemical reaction of the assay is the oxidative degradation of 2-
deoxy-D-ribose by hydroxyl radicals arising in the Fenton reaction
[17,23,24]. The oxidation of 2-deoxy-D-ribose leads to the produc-
tion of thiobarbituric acid reactive species (TBARS). The reaction
mixture contains hydrogen peroxide, iron(III) and ascorbic acid.
Ascorbic acid starts the Fenton reaction by reduction of iron(III) to
iron(II). Iron is added either as FeCl3 or in complex with ethyl-
enediaminetetraacetic acid (EDTA). Ascorbic acid is used because it
is known as a common cellular reducing agent. If iron ions are
added as FeCl3, they can form complexes with the test compound,
as EDTA complex this is less likely to occur. Further modiﬁcations of
this assay, for example if hydrogen peroxide and/or ascorbic acid
are not added, provide additional information about the redox
chemistry of the test compounds [17]. The variants of theituric acid reactive species in variants of deoxyribose degradation assay. EDTA, ethyl-
etters (aeh) indicate different levels of signiﬁcance (95% Duncan).
V. Chobot et al. / Journal of Organometallic Chemistry 782 (2015) 103e110108deoxyribose degradation assay in which hydrogen peroxide is
added, more or less create a tissue damage scenario with relatively
high ROS concentrations.
ANA and 3-HANA proved as efﬁcient antioxidants in the H2O2/
FeIII/ascorbic acid and FeIII/ascorbic acid deoxyribose degradation
assay variants (Fig. 4aed). The results of assay variants with or
without EDTA addition suggested further that both iron chelation
and ROS scavenging may have contributed to the observed effect.
No pro-oxidant effects were observed, which can be interpreted
that ANA and 3-HANA were not able to substitute the function of
ascorbic acid in the FeIII or H2O2/FeIII assay variants (data not
shown). In contrast, Iwahashi et al. observed that 3-HANA
increased hydroxyl radical production in reaction mixtures con-
taining iron(III) and hydrogen peroxide or superoxide dismutase;
the concentrations of hydroxyl radicals were determined by EPR
(electron paramagnetic resonance) [14]. Furthermore, various au-
thors have provided evidence that 3-HANA can reduce iron(III) to
iron(II) in phosphate buffer solution of pH 7.4 [14,15]. These con-
tradictions in the results can be explained by the different experi-
mental arrangements that were used by the various authors.
Moreover, the other authors did not explore oxidative degradation
of 2-deoxy-D-ribose such as it is the case in this study. In the
iron(III) reduction assay, they employed a spectrophotometric
determination of iron(II) concentrations by iron(II) chelators,
bathophenanthroline disulfonic acid or phenanthroline [14,15]. It
cannot be ruled out that the used iron(II) chelators could have
shifted the reaction equilibrium towards iron reduction [25].
To clarify the contradictions, we performed an iron(II) autoxi-
dation assay [18,19]. In this assay, ANA and 3-HANA showed
different effects (Fig. 5). Whereas ANA inhibited generation of
TBARS in a concentration range of 63e500 mM (Fig. 5a), 3-HANA
showed apparent pro-oxidant activity between the concentra-
tions of 31 and 500 mM (Fig. 5b). Iron(II) is oxidized by molecular
oxygen which is reduced to superoxide anion radical. This radical
can spontaneously dismutate or be reduced to hydrogen peroxide.
Then, hydrogen peroxide starts the Fenton reaction and hydroxyl
radical production. Hydroxyl radicals are detected as TBARS
(2-deoxy-D-ribose decomposition products). In this assay, iron does
not require to be reduced before participation in the Fenton reac-
tion [19]. The test compound can inﬂuence TBARS generation by
affecting of iron(II) autoxidation rate and/or by ROS scavenging.
Both mechanisms can contribute to the antioxidant activity of
ANA. If iron is a central atom in coordination complexes with ANA,
the redox potential of iron is shifted into the anodic direction as
shown by differential pulse voltammetry. An anodic shift decreasesFig. 5. Effects of anthranilic acid and 3-hydroxyanthranilic acid on generation of thiobarbitu
deviation of three replicates; letters (aeg) indicate different levels of signiﬁcance (95% Dunthe rate of iron(II) autoxidation. Furthermore, the 2-amino group
can also contribute to the antioxidant effect of ANA by hydroxyl
radical scavenging.
The pro-oxidant effect of 3-HANA in the iron(II) autoxidation
assay can be explained by semiquinone formation. The hydroxyl
group of 3-HANA can be oxidized to a semiquinone by superoxide
anion radical, a reaction product of iron(II) autoxidation. Semi-
quinones and their derivatives are potent reducing agents which
can reduce molecular oxygen to superoxide anion radical [26] that
can dismutate to hydrogen peroxide. The dismutation can occur
either spontaneously or catalyzed by irone3-HANA complexes [27].
Superoxide anion radical may be reduced also to hydrogenperoxide
by a further molecule of 3-HANA. Both processes, dismutation and
reduction of superoxide radical, lead to quick formation of
hydrogen peroxide which enters in the Fenton reaction generating
hydroxyl radicals.
The nano-ESIeMS analyses of ANA and 3-HANA oxidation
stability conﬁrmed higher redox reactivity of the latter compared to
the former (Fig. 6). The exploration of oxidation stability was car-
ried out in the Fenton reaction mixture containing hydrogen
peroxide and iron(II). The reaction mixtures were analyzed after
reaction times of 3 and 8 h by direct infusion. After 3 h, the ions of
both tested acids were detectable (Fig. 6 c,d). After 8 h, the 3-HANA
ion had vanished from the mass spectrum and numerous new ions
with lower and higher masses appeared. By contrast, ANA was still
present in the analyzed solution (Fig. 6 e,f). In addition, the mass
spectrum of 3-HANA that was recorded after 8 h incubation showed
more ions of reaction products than of the ANA ion itself.
Changing ANA and 3-HANA concentrations as well as their
actual ratio in tissues can modulate T-cell activity in the immune
system. 3-HANA can also affect various inﬂammatory factors [7,28].
A decreasing concentration ratio 3-HANA:ANA was detected in
brains of patients suffering from some neurological diseases such as
stroke, chronic brain injury and Huntington's disease [6,7]. The
altered levels of 3-HANA can lead to modiﬁed inﬂammatory and
immune system responses often associated with the above-
mentioned diseases. Several hypotheses propose causes for this
decreasing ratio, but none of them explains fully all aspects of the
phenomenon. One of many possible mechanisms, which could lead
to decreasing 3-HANA concentrations, is the reaction of 3-HANA
with hydroxyl radical under oxidative stress conditions. 3-HANA
is more susceptible to oxidation by ROS than ANA. The produc-
tion of hydroxyl radicals in brains of patients can be enhanced by
accumulation of transition metals, especially iron [8,29], which
initializes the Fenton reaction.ric acid reactive species in iron(II) autoxidation assay. Error bars indicate the standard
can).
Fig. 6. ESIeMS spectra in the positive mode of anthranilic acid (ANA) and 3-hydroxyanthranilic acid (3-HANA) degradation in the presence of iron(II) and hydrogen peroxide.
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Both, ANA and 3-HANA, are redox active and can act as anti-
oxidants in certain chemical environments. Furthermore they form
coordination complexes with iron. A combination of differential
pulse voltammetry, deoxyribose degradation assay, iron(II)-
autoxidation assay and direct infusion ESIeMS of coordination
complexes and oxidation reaction solutions succeeded in revealing
some minor but important differences in the redox chemistry of
these two tryptophan metabolites. 3-HANA is much more instable
than ANAwhen attacked by hydroxyl radicals in an oxidative stress
scenario. The high redox reactivity of 3-HANA, especially in pres-
ence of iron(II), concurs with the observation that patients suffering
from various neurological diseases (e.g. stroke, chronic brain injury
and Huntington's disease) show decreased levels of this metabolite.
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